Neurocutaneous Melanosis Associated with Malignant Leptomeningeal Melanoma in an Adult: Clinical Significance of 5-S-Cysteinyldopa in the Cerebrospinal Fluid - Case Report

Neurologia Medico-Chirurgica

Volumn 43, Issue 12, 2003, Pages 619-625

  Shinno, Kiyohito ^a,b   Nagahiro, Shinji ^a   Uno, Masaaki ^a   Kannuki, Seiji ^a   Nakaiso, Mami ^a   Sano, Nobuya ^a   Horiguchi, Hidehisa ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b National Hospital Organization   (Japan)

Author keywords

5 S cysteinyldopa; Hydrocephalus; Leptomeninges; Melanoma; Pigmented nevus

Indexed keywords

ANTINEOPLASTIC AGENT; BETA INTERFERON; CISPLATIN; CYSTEINYLDOPA; DACARBAZINE; VINDESINE;

ADULT; ARTICLE; BRAIN BIOPSY; BRAIN VENTRICLE PERITONEUM SHUNT; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CASE REPORT; CEREBROSPINAL FLUID LEVEL; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; HUMAN; HUMAN TISSUE; HYDROCEPHALUS; LEPTOMENINX; MALE; MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PHAKOMATOSIS; PIGMENTED NEVUS; POSTOPERATIVE CARE; TREATMENT OUTCOME;

ADULT; BIOPSY; CYSTEINYLDOPA; FATAL OUTCOME; HUMANS; HYDROCEPHALUS; MALE; MELANOMA; MELANOSIS; MENINGEAL NEOPLASMS; NEUROCUTANEOUS SYNDROMES; VENTRICULOPERITONEAL SHUNT;

EID: 0942276882     PISSN: 04708105     EISSN: None     Source Type: Journal    
DOI: 10.2176/nmc.43.619     Document Type: Article

References (26)

1. Agrup G, Andersson T, Falck B, Persson K, Rorsman H, Rosengren A-M, Rosengren E: 5-S-cysteinyldopa in the plasma of melanoma patients and the renal clearance of this amino acid. Acta Derm Venereol 55: 5-6, 1975
2. Allcutt D, Michowiz S, Weitzman S, Becker L, Blaser S, Hoffman HJ, Humphreys RP, Drake JM, Rutka JT: Primary leptomeningeal melanoma: An unusually aggressive tumor in childhood. Neurosurgery 32: 721-729, 1993
3. Bamborschke S, Ebhardt G, Szelies-Stock B, Dreesbach HA, Heiss W-D: Review and case report: Primary melanoblastosis of the leptomeninges. Clin Neuropathol 4: 47-55, 1985
4. Chiba M, Jimbow K, Kizukuri K, Homma K: Chemoimmunotherapy for disseminated malignant melanoma with DTIC, ACNU, VCR and OK432. J Dermatol 9: 23-30, 1982
5. Faillance WJ, Okawara S-H, McDonald JV: Neurocutaneous melanosis with extensive intracerebral and spinal cord involvement. J Neurosurg 61: 782-785, 1984
6. Fox H: Neurocutaneous melanosis, in Vinken PJ, Bruyn GW (eds): The Phakomatoses. Handbook of Clinical Neurology, vol 14. Amsterdam, Elsevier, 1972, pp 414-428
7. Habermalz HJ, Fischer JJ: Radiation therapy of malignant melanoma - Experience with high individual treatment doses. Cancer 38: 2258-2262, 1976
8. Hansson C, Agrup G, Rorsman H, Rosengren A-M, Rosengren E: An analysis of cysteinyldopas, dopa, dopamine, noradrenaline and adrenaline in serum and urine using high-performance liquid chromatography and electrochemical detection. J Chromatogr 162: 7-22, 1979
9. Hara H, Chino K, Kawanami T, Sameshima T, Morishima T: 5-S-cysteinyldopa in urine and tumors. J Dermatol 19: 806-808, 1992
10. Hoffman HJ, Freeman A: Primary malignant leptomeningeal melanoma in association with giant hairy nevi. J Neurosurg 26: 62-71, 1967
11. Horikoshi T, Ito S: Serum 5-S-cysteinyldopa (5-S-CD) as a marker of melanoma progression. J Dermatol 19: 809-813, 1992
12. Humes RA, Roskamp J, Eisenbrey AB: Melanosis and hydrocephalus. J Neurosurg 61: 365-368, 1984
13. Jönsson P-E, Agrup G, Arnbjörnsson E, et Hafström LO, Rorsman H: Treatment of malignant melanoma with dacarbazin (DTIC-DOME) with special reference to urinary excretion of 5-S-cysteinyldopa. Cancer 45: 245-248, 1980
14. Kadonaga JN, Frieden IJ: Neurocutaneous melanosis: Definition and review of the literature. J Am Acad Dermatol 24: 747-755, 1991
15. Kaplan AM, Itabashi HH, Hanelin LG, Lu AT: Neurocutaneous melanosis with malignant leptomeningeal melanoma. Arch Neurol 32: 669-671, 1975
16. Nakagawa H, Hayakawa T, Niiyama K, Nii Y, Yoshimine T, Mori S: Long-term survival after removal of primary intracranial malignant melanoma. Case report. Acta Neurochir (Wien) 101: 84-88, 1989
17. Pascual-Castroviejo I: Neurocutaneous melanosis, in Gomez M (ed): Neurocutaneous Diseases. Boston, Butterworth, 1987, pp 329-334
18. Pectasides D, Yianniotis H, Alevizakos N, Bafaloukos D, Barbounis V, Varthalitis J, Dimitriadis M, Athanassiou A: Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin. Br J Cancer 60: 627-629, 1989
19. Peterson LL, Woodward WR, Fletcher WS, Palmquist M, Tucker MA, Ilias A: Plasma 5-S-cysteinyldopa differentiates patients with primary and metastatic melanoma from patients with dysplastic nevus syndrome and normal subjects. J Am Acad Dermatol 19: 509-515, 1988
20. Reed WB, Becker SW Sr, Becker SW Jr, Nickel WR: Giant pigmented nevi, melanoma, and leptomeningeal melanocytosis. A clinical and histopathological study. Arch Dermatol 91: 100-119, 1965
21. Slaughter JC, Hardman JM, Kempe LG, Earle KM: Neurocutaneous melanosis and leptomeningeal melanomatosis in children. Arch Pathol 88: 298-304, 1969
22. Thomas CS, Toone BK, Rose PE: Neurocutaneous melanosis and psychosis. Am J Psychiatry 145: 649-650, 1988 (letter)
23. Vasdev A, David P, Villemot D, Bennani W, Pascal-Ortiz D, Pasquier B, Chirossel JP, Le-Bas JF: Apparently primary malignant melanoma of the cerebellopontine angle. One case. J Neuroradiol 17: 152-156, 1990
24. Verschraegen CF, Kleeberg YR, Mulder J, Rumke P, Truchetet F, Czarnetzki B, Rozencweig M, Thomas D, Suciu S: Combination of cisplatin, vindesine, and dacarbazine in advanced malignant melanoma. A phase II study of the EORTC malignant melanoma cooperative group. Cancer 62: 1061-1065, 1988
25. Williams HI: Primary malignant meningeal melanoma associated with giant hairy nevi. J Pathol Bacteriol 99: 171-174, 1969
26. Woodruff WW Jr, Djang WT, McLendon RE, Heinz ER, Voorhees DR: Intracerebral malignant melanoma: high-field-strength MR imaging. Radiology 165: 209-213, 1987